Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-08-17
2003-01-21
Kumar, Shailendra (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S146000, C562S575000
Reexamination Certificate
active
06509350
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to the use of certain acid donors as stabilizers in pharmaceutical compositions, and to the stabilized pharmaceutical compositions resulting therefrom.
There are a number of pharmaceutical compositions which suffer from instability problems due to the fact that the active component is susceptible to certain types of degradation, thereby diminishing their attractiveness and, in some cases, rendering them unsuitable from a commercial standpoint. For example, several ACE (Angiotensin Converting Enzyme) inhibitor-containing compositions suffer from this drawback since certain ACE inhibitors degrade readily in pharmaceutical dosage forms. More particularly, and as is the case with other ACE inhibitors such as Quinapril and Enalapril, Spirapril degrades readily in dosage forms to the diketo piperazine (the internal cyclization product) and the diacid (the ester hydrolysis product). Accordingly, in view of their usefulness in treating hypertension, a number of research endeavors have been directed to overcoming the instability problem associated with ACE inhibitor-containing compositions, without appreciable success.
DESCRIPTION OF THE PRIOR ART
European Patent Application 264,888 is directed to the stabilization of ACE inhibitor-containing pharmaceutical compositions employing ascorbic acid alone or a combination of ascorbic acid with fumaric acid, maleic acid and/or citric acid as the stabilizing component(s).
U.S. Pat. No. 4,743,450 is also directed to the stabilization of ACE inhibitor-containing pharmaceutical compositions employing, as the stabilizer component, a combination of an alkali or alkaline earth metal salt (preferably, magnesium carbonate) and a saccharide (preferably, mannitol or lactose).
Although each of the above patents represents an attempt to overcome the instability problems associated with ACE inhibitor-containing compositions, there still exists a dire need for ACE inhibitor-containing compositions exhibiting improved stability, especially in the presence of moisture. To this end, the present invention is directed to pharmaceutical compositions, particularly ACE inhibitor-containing compositions, exhibiting improved stability.
OBJECTS OF THE INVENTION
It is, therefore, an object of the present invention to provide new stabilized pharmaceutical compositions.
It is another object of the present invention to provide new stabilized pharmaceutical compositions comprising a select group of acid donors as the stabilizing component thereof.
It is still another object of the present invention to provide new stabilized ACE inhibitor-containing pharmaceutical compositions.
It is yet still another object of the present invention to provide new stabilized ACE inhibitor-containing pharmaceutical compositions comprising a select group of acid donors as the stabilizing component thereof.
ADVANTAGES OF THE INVENTION
The stabilized pharmaceutical compositions of the instant invention exhibit a number of advantages as follows:
1) The active component, e.g., an ACE inhibitor, is virtually preserved from any type of degradation.
2) They exhibit an extended shelf-life under normal storage conditions.
3) They are insensitive to moisture and, in fact, the stability improves with an increase in moisture.
4) They exhibit minimal, if any, discoloration over a significant period of time.
5) They exhibit minimal, if any, instability when employed in the presence of colorants.
REFERENCES:
patent: 4344949 (1982-08-01), Hoefle et al.
patent: 4470972 (1984-09-01), Gold et al.
patent: 4500713 (1985-02-01), Suh et al.
patent: 4743450 (1988-05-01), Harris et al.
patent: 4793998 (1988-12-01), Murthy et al.
patent: 4808413 (1989-02-01), Joshi et al.
patent: 4808608 (1989-02-01), Guindon et al.
patent: 4830853 (1989-05-01), Murthy et al.
patent: 4912096 (1990-03-01), Sudilovsky
patent: 4940719 (1990-07-01), Gillard et al.
patent: 4952566 (1990-08-01), Sakamaki et al.
patent: 5158777 (1992-10-01), Abramowitz et al.
patent: 12401 (1980-06-01), None
patent: 264887 (1988-04-01), None
patent: 264888 (1988-04-01), None
patent: 895027 (1962-04-01), None
patent: 1317234 (1973-05-01), None
patent: 1437788 (1976-06-01), None
patent: 2101484 (1983-01-01), None
patent: 87/06048 (1988-04-01), None
patent: 88/08734 (1989-07-01), None
Merck Index Disclosure 4682, 1983.
Physical Pharmacy, p. 389 (1983).
Pharmaceutical Research, vol. 4, No. 5, pp. 392-397 (1987).
J.Med.Chem., vol. 32, pp. 1600-1606 (1989).
Ross Bruce A.
Vivilecchia Richard V.
Borovian Joseph J.
Kumar Shailendra
Novartis AG
LandOfFree
Stabilized pharmaceutical compositions comprising acid donors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized pharmaceutical compositions comprising acid donors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized pharmaceutical compositions comprising acid donors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3024149